Sol Gel Net Income Over Time
| SLGL Stock | USD 60.85 2.65 4.17% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Sol Gel Performance and Sol Gel Correlation. Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sol Gel. If investors know Sol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Sol Gel assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 4.876 | Earnings Share (1.22) | Revenue Per Share | Quarterly Revenue Growth 2.177 | Return On Assets |
Investors evaluate Sol Gel Technologies using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Sol Gel's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Sol Gel's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Sol Gel's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sol Gel is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Sol Gel's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare Sol Gel Technologies and related stocks such as OKYO Pharma, Clene Inc, and Coya Therapeutics Common Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OKYO | (3 M) | (4.8 M) | (4.8 M) | (13.9 M) | (8.3 M) | (820.2 K) | (241.9 K) | (28.3 M) | (4.9 M) | (1.5 M) | (3.4 M) | (5.4 M) | (13.3 M) | (16.8 M) | (4.7 M) | (4.2 M) | (4.4 M) |
| CLNN | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (2.4 K) | (277.3 K) | (16.2 M) | (19.3 M) | (9.7 M) | (29.9 M) | (49.5 M) | (39.4 M) | (35.5 M) | (33.7 M) |
| COYA | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (4.9 M) | (12.2 M) | (8 M) | (14.9 M) | (13.4 M) | (12.7 M) |
| TLSA | (272 K) | (1.2 M) | (848 K) | (280 K) | (3.5 M) | (12.8 M) | (7.2 M) | (6.8 M) | (6.3 M) | (7.3 M) | (26.1 M) | (23.4 M) | (15.4 M) | (17.7 M) | (11.9 M) | (10.7 M) | (10.1 M) |
| PLRX | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (30.3 M) | (631 K) | (39.7 M) | (17.9 M) | (123.3 M) | (161.3 M) | (210.3 M) | (189.3 M) | (179.8 M) |
| MGNX | 6.7 M | 6.7 M | 8.4 M | (260.8 K) | (38.3 M) | (20.1 M) | (58.5 M) | (19.6 M) | (171.5 M) | (151.8 M) | (117.8 M) | (190.9 M) | (120 M) | (9.1 M) | (67 M) | (60.3 M) | (63.3 M) |
| ZNTL | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (45.7 M) | (117.8 M) | (158.7 M) | (236.8 M) | (292.2 M) | (165.8 M) | (149.3 M) | (156.7 M) |
| ANEB | (174.6 K) | (174.6 K) | (174.6 K) | (174.6 K) | (174.6 K) | (174.6 K) | (174.6 K) | (174.6 K) | (174.6 K) | (174.6 K) | (30.3 M) | (6.8 M) | (11.7 M) | (8.2 M) | (8.5 M) | (9.8 M) | (10.2 M) |
| OVID | (447 K) | (447 K) | (447 K) | (447 K) | (447 K) | (13.2 M) | (22.4 M) | (64.8 M) | (52 M) | (59.3 M) | (80.7 M) | 122.8 M | (51.4 M) | (52.3 M) | (26.4 M) | (23.8 M) | (25 M) |
| ORMP | (50 K) | (1.6 M) | (3.3 M) | (4.2 M) | (5.7 M) | (7.2 M) | (11 M) | (10.5 M) | (12.7 M) | (14.4 M) | (11.5 M) | (22.2 M) | (37.8 M) | 5.5 M | (19.1 M) | (17.2 M) | (16.3 M) |
Sol Gel Technologies and related stocks such as OKYO Pharma, Clene Inc, and Coya Therapeutics Common Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Sol Gel Technologies financial statement analysis. It represents the amount of money remaining after all of Sol Gel Technologies operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Sol Gel Technologies | SLGL |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 7 Golda Meir |
| Exchange | NASDAQ Exchange |
USD 60.85
Check out Sol Gel Performance and Sol Gel Correlation. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Sol Gel technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.